The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma - Individual patient data from 1775 patients in four randomised controlled trials

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 885-891

  Chau, I ^a   Norman, A R ^a   Cunningham, David ^a   Oates, J ^a   Hawkins, R ^b   Iveson, T ^c   Nicolson, M ^d   Harper, P ^e   Seymour, M ^f   Hickish, T ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Gastric adenocarcinoma; Oesophago gastric junction; Oesophagus

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; SURVIVAL TIME;

EID: 65549103309     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn716     Document Type: Article

References (33)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002-Cancer Incidence, Mortality and Prevalence Worldwide, Version 2.0. 2004.
2. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
3. Kang Y, Kang WK, Shin DB et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts) 2006; 24: (Abstr LBA4018).
4. Ohtsu A, Shimada Y, Shirao K et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59.
5. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
6. Wils JA, Klein HO, Wagener DJ et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
7. Douglass HO Jr, Lavin PT, Goudsmit A et al. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372-1381.
8. Cullinan SA, Moertel CG, Wieand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994; 12: 412-416.
9. Cocconi G, Carlini P, Gamboni A et al. Cisplatin, epirubicin, leucovorin and 5- fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003; 14: 1258-1263.
10. Al Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
11. Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-1457.
12. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
13. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999; 80: 269-272.
14. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
15. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004.
16. Tebbutt NC, Norman A, Cunningham D et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5- FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002; 13: 1568-1575.
17. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
18. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Peto R, Peto J. Asymptotically efficient invariant procedures. J R Stat Soc A 1972; 135: 185-206.
20. Cox DR. Regression models and life tables. J R Stat Soc A 1972; 29: 187-220.
21. Chau I, Norman AR, Cunningham D et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004; 22: 2395-2403.
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
23. Ectors N, Driessen A, De Hertog G et al. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med 2005; 129: 183-185.
24. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2-9.
25. Gomes LI, Esteves GH, Carvalho AF et al. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: Differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005; 65: 7127-7136.
26. Adelstein DJ, Rybicki LA, Carroll MA et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. J Clin Oncol (Meeting Abstracts) 2005; 23: (Abstr 4054).
27. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927.
28. Ferry DR, Anderson M, Beddard K et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13: 5869-5875.
29. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-1619.
30. Radovich D, Kelsen D, Shah M et al. OSI-774 in advanced esophageal cancer: A phase II study. J Clin Oncol (Meeting Abstracts) 2004; 22: (Abstr 4077).
31. Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316.
32. Tew WP, Shah M, Schwartz G et al. Phase II trial of erlotonib for second-line treatment in advanced esophageal cancer. Gastrointestinal Cancers Symposium. 2005; (Abstr 5).
33. Bang Y, Chung H, Sawaki A et al. HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial. J Clin Oncol (Meeting Abstracts) 2008; 26: (Abstr 4526).